Di W - Search Results

1

Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.

Cheng L, Zhou S, Zhou S, Shi K, Cheng Y, Cai MC, Ye K, Lin L, Zhang Z, Jia C, Xiang H, Zang J, Zhang M, Yin X, Li Y, Di W, Zhuang G, Tan L. Cheng L, et al. Among authors: di w. Cancer Res. 2022 Oct 4;82(19):3588-3602. doi: 10.1158/0008-5472.CAN-22-0222. Cancer Res. 2022. PMID: 35857807

2

Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.

Zhang N, Wu ZM, McGowan E, Shi J, Hong ZB, Ding CW, Xia P, Di W. Zhang N, et al. Among authors: di w. Cancer Sci. 2009 Dec;100(12):2459-64. doi: 10.1111/j.1349-7006.2009.01340.x. Epub 2009 Sep 2. Cancer Sci. 2009. PMID: 19769630 Free PMC article.

3

Regulation of LC3-dependent protective autophagy in ovarian cancer cells by protein phosphatase 2A.

Yin X, Zhang N, Di W. Yin X, et al. Among authors: di w. Int J Gynecol Cancer. 2013 May;23(4):630-41. doi: 10.1097/IGC.0b013e3182892cee. Int J Gynecol Cancer. 2013. PMID: 23518861

4

Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer.

Wang Y, Wang Y, Xiang J, Ji F, Deng Y, Tang C, Yang S, Xi Q, Liu R, Di W. Wang Y, et al. Among authors: di w. Cancer Lett. 2014 Feb 1;343(1):6-13. doi: 10.1016/j.canlet.2013.09.002. Epub 2013 Sep 7. Cancer Lett. 2014. PMID: 24018641

5

Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.

Wang Y, Liu P, Duan Y, Yin X, Wang Q, Liu X, Wang X, Zhou J, Wang W, Qiu L, Di W. Wang Y, et al. Among authors: di w. Biomaterials. 2014 Jan;35(3):983-92. doi: 10.1016/j.biomaterials.2013.09.062. Epub 2013 Oct 28. Biomaterials. 2014. PMID: 24176193

6

Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies.

Liu T, Chen L, Sun X, Wang Y, Li S, Yin X, Wang X, Ding C, Li H, Di W. Liu T, et al. Among authors: di w. Tumour Biol. 2014 Mar;35(3):2427-36. doi: 10.1007/s13277-013-1322-x. Epub 2013 Nov 7. Tumour Biol. 2014. PMID: 24197980

7

[Risk of cervical cancer and precancerous diseases in the oral HPV carriers].

He YF, Zhang MY, Feng LD, Yin YH, Zhang R, Di W. He YF, et al. Among authors: di w. Zhonghua Fu Chan Ke Za Zhi. 2013 Aug;48(8):611-6. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24199928 Chinese.

8

High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.

He YF, Zhang MY, Wu X, Sun XJ, Xu T, He QZ, Di W. He YF, et al. Among authors: di w. PLoS One. 2013 Dec 6;8(12):e79769. doi: 10.1371/journal.pone.0079769. eCollection 2013. PLoS One. 2013. PMID: 24324582 Free PMC article.

9

A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.

Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, Di W. Zhang M, et al. Among authors: di w. J Ovarian Res. 2014 Feb 8;7:19. doi: 10.1186/1757-2215-7-19. J Ovarian Res. 2014. PMID: 24507759 Free PMC article.

10

MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.

Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, Di W, Qiu L. Zhou X, et al. Among authors: di w. PLoS One. 2014 May 9;9(5):e96718. doi: 10.1371/journal.pone.0096718. eCollection 2014. PLoS One. 2014. PMID: 24816687 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

679 results

Search Page

Filters